糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-世界市場予測2023-2030

糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場は大きく成長し、2023年には3億7,638万米ドル、CAGR 17.62%と予測され、2030年には11億7,720万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場規模および予測は？

2.予測期間中、世界の糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場を形成するCOVID-19の阻害要因と影響は？

3.糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場における競争戦略は？

5.糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場における技術動向と規制の枠組みは？

6.糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場における主要ベンダーの市場シェアは？

7.糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に糖尿病の有病率が上昇
    • 糖尿病の管理とケアに関する意識の向上
    • 糖尿病管理を促進するための政府の取り組み
  • 抑制要因
    • 熟練した眼科医が不足している
  • 機会
    • 先進的な糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界治療法と薬剤の継続的なイントロダクション
    • 糖尿病黄斑浮腫治療のための併用療法の登場
  • 課題
    • 糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界医薬品の承認プロセスに時間がかかる
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場：タイプ別

• 非増殖性DR
• 増殖性DR

第7章 糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場管理者別

• 抗VEGF療法
• ステロイド眼内注射
• レーザー手術
• 硝子体手術

第8章 南北アメリカの糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの糖尿病網膜症：タイプ別（非増殖性DR、増殖性DR）、管理（抗VEGF療法、眼内ステロイド注射、レーザー手術）-ロシア・ウクライナ紛争と高インフレ-世界市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
• FIGURE 2. DIABETIC RETINOPATHY MARKET SIZE, 2022 VS 2030
• FIGURE 3. DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2022 VS 2030 (%)
• FIGURE 6. DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. DIABETIC RETINOPATHY MARKET DYNAMICS
• FIGURE 8. DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 8. DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. DIABETIC RETINOPATHY MARKET SIZE, BY INTRAOCULAR STEROID INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. DIABETIC RETINOPATHY MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. DIABETIC RETINOPATHY MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 15. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 17. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 19. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 21. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 29. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 31. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 33. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 35. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 37. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 39. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 41. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 43. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 45. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 47. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 49. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 51. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 56. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 58. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 60. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 62. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 64. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 66. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 68. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 70. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 72. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 74. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 76. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 78. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 80. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 82. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 86. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 88. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 90. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 92. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 94. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 96. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 98. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 99. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 100. DIABETIC RETINOPATHY MARKET LICENSE & PRICING

The Global Diabetic Retinopathy Market is forecasted to grow significantly, with a projected USD 376.38 million in 2023 at a CAGR of 17.62% and expected to reach a staggering USD 1,177.20 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Diabetic Retinopathy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Diabetic Retinopathy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Non-proliferative DR and Proliferative DR. The Proliferative DR is projected to witness significant market share during forecast period.

Based on Management, market is studied across Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy. The Laser Surgery is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Diabetic Retinopathy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetic Retinopathy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetic Retinopathy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetic Retinopathy Market?

4. What is the competitive strategic window for opportunities in the Global Diabetic Retinopathy Market?

5. What are the technology trends and regulatory frameworks in the Global Diabetic Retinopathy Market?

6. What is the market share of the leading vendors in the Global Diabetic Retinopathy Market?

7. What modes and strategic moves are considered suitable for entering the Global Diabetic Retinopathy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Diabetic Retinopathy Market, by Type, 2022 vs 2030
• 4.3. Diabetic Retinopathy Market, by Management, 2022 vs 2030
• 4.4. Diabetic Retinopathy Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of diabetes globally
    • 5.1.1.2. Increasing awareness associated with diabetic management and care
    • 5.1.1.3. Government initiatives to promote the diabetes management
  • 5.1.2. Restraints
    • 5.1.2.1. Dearth of skilled ophthalmologists
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing introduction of advanced diabetic retinopathy treatments and drugs
    • 5.1.3.2. Emergence of combine therapies for treatment of diabetic macular edema
  • 5.1.4. Challenges
    • 5.1.4.1. Time consuming approval process for diabetic retinopathy drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Diabetic Retinopathy Market, by Type

• 6.1. Introduction
• 6.2. Non-proliferative DR
• 6.3. Proliferative DR

7. Diabetic Retinopathy Market, by Management

• 7.1. Introduction
• 7.2. Anti-VEGF Therapy
• 7.3. Intraocular Steroid Injection
• 7.4. Laser Surgery
• 7.5. Vitrectomy

8. Americas Diabetic Retinopathy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Diabetic Retinopathy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Retinopathy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

1. Alimera Sciences, Inc.

2. Allergan PLC

3. Ampio Pharmaceuticals, Inc.

4. Bausch & Lomb Incorporated

5. Bayer AG

6. BCN PEPTIDES, S.A.U.

7. F. Hoffmann-La Roche AG

8. Kodiak Sciences Inc.

9. Kowa Company, Ltd.

10. Novartis AG

11. Opthea Limited

12. Oxurion NV

13. Pfizer Inc.

14. Regeneron Pharmaceuticals Inc.

15. Sirnaomics Inc.